BlackRock Health Sciences Term Trust (NYSE:BMEZ) Major Shareholder Purchases 126,910.08 in Stock

BlackRock Health Sciences Term Trust (NYSE:BMEZ) major shareholder Saba Capital Management, L.P. acquired 8,012 shares of the company’s stock in a transaction on Monday, September 30th. The stock was bought at an average cost of 15.84 per share, with a total value of 126,910.08. Following the completion of the acquisition, the insider now directly owns 20,661,390 shares in the company, valued at 327,276,417.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Friday, September 27th, Saba Capital Management, L.P. purchased 1,633 shares of BlackRock Health Sciences Term Trust stock. The stock was bought at an average price of 15.89 per share, for a total transaction of 25,948.37.
• On Wednesday, September 25th, Saba Capital Management, L.P. acquired 300 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average cost of 15.73 per share, with a total value of 4,719.00.
• On Monday, September 23rd, Saba Capital Management, L.P. acquired 2,006 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average price of 15.98 per share, for a total transaction of 32,055.88.
• On Thursday, September 19th, Saba Capital Management, L.P. bought 15,455 shares of BlackRock Health Sciences Term Trust stock. The stock was purchased at an average price of 16.14 per share, with a total value of 249,443.70.
• On Tuesday, September 17th, Saba Capital Management, L.P. purchased 27,148 shares of BlackRock Health Sciences Term Trust stock. The shares were purchased at an average price of 15.93 per share, for a total transaction of 432,467.64.

BlackRock Health Sciences Term Trust Stock Performance

Shares of BMEZ opened at 15.76 on Friday. The firm has a 50 day simple moving average of 15.85 and a two-hundred day simple moving average of 15.53. BlackRock Health Sciences Term Trust has a one year low of 12.93 and a one year high of 16.59.

BlackRock Health Sciences Term Trust Dividend Announcement

The firm also recently disclosed a monthly dividend, which will be paid on Thursday, October 31st. Investors of record on Tuesday, October 15th will be paid a $0.176 dividend. This represents a $2.11 annualized dividend and a yield of 13.40%. The ex-dividend date is Tuesday, October 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. boosted its stake in shares of BlackRock Health Sciences Term Trust by 21.7% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 5,830 shares of the company’s stock valued at $96,000 after purchasing an additional 1,038 shares in the last quarter. Register Financial Advisors LLC boosted its position in BlackRock Health Sciences Term Trust by 5,365.6% in the second quarter. Register Financial Advisors LLC now owns 6,832 shares of the company’s stock valued at $105,000 after buying an additional 6,707 shares in the last quarter. Shaker Financial Services LLC bought a new stake in shares of BlackRock Health Sciences Term Trust during the second quarter worth $184,000. Comerica Bank increased its holdings in shares of BlackRock Health Sciences Term Trust by 31.1% during the first quarter. Comerica Bank now owns 15,469 shares of the company’s stock worth $254,000 after buying an additional 3,671 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of BlackRock Health Sciences Term Trust in the 1st quarter valued at $285,000.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.